Minireviews
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 28, 2024; 30(8): 833-842
Published online Feb 28, 2024. doi: 10.3748/wjg.v30.i8.833
Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect
Xiao-Xia Qiu, Sheng-Li Cheng, Yan-Hui Liu, Yu Li, Rui Zhang, Nan-Nan Li, Zheng Li
Xiao-Xia Qiu, Research and Education Department, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou 310022, Zhejiang Province, China
Sheng-Li Cheng, Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230000, Anhui Province, China
Yan-Hui Liu, Department of Clinical Pharmacy, Anhui Provincial Children’s Hospital, Hefei 230000, Anhui Province, China
Yu Li, Department of Pharmacy, Taihe County People’s Hospital of Anhui Province, Fuyang 236600, Anhui Province, China
Rui Zhang, Department of Pharmacy, The Second People’s Hospital of Hefei, Hefei Hospital Affiliated to Anhui Medical University, Hefei 230000, Anhui Province, China
Nan-Nan Li, University of Science and Technology of China, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, Anhui Province, China
Zheng Li, Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells, College of Health Sciences, School of Life Sciences, Jiangsu Normal University, Xuzhou 221000, Jiangsu Province, China
Co-first authors: Xiao-Xia Qiu and Sheng-Li Cheng.
Co-corresponding authors: Nan-Nan Li and Zheng Li.
Author contributions: Qiu XX and Cheng SL contributed to the acquisition of data; Qiu XX, Cheng SL, Liu YH, Li Y, and Zhang R contributed to the analysis and interpretation of data; Qiu XX, Cheng SL, Liu YH, Li NN, and Li Z drafted the article; Liu YH, Li Y, Zhang R, Li NN, and Li Z revised the article; Li NN and Li Z contributed to the conception and design of the study, and critical revision; all authors contributed to the final approval of the article. Qiu XX and Cheng SL contributed equally to this work as co-first authors; Li NN and Li Z contributed equally to this work as co-corresponding authors. The reasons for designating co-first or co-corresponding authors are as follows: (1) The research was performed as a collaborative effort, and the designation of co-first/co-corresponding authorship accurately reflects the distribution of responsibilities and contribution to the study; (2) the designation reflects the diversity of expertise and skills of the overall research team; and (3) these authors contributed efforts of equal substance throughout the research process. In summary, we believe that this designation is fitting for our manuscript as it accurately reflects our team's collaborative spirit, equal contributions, and diversity.
Supported by the National Natural Science Foundation of China, No. 82104525; the Natural Science Foundation of the Jiangsu Higher Education Institutions of China, No. 21KJB360009; and Health Commission of Zhejiang Province Scientific Research Foundation, No. 2024KY247.
Conflict-of-interest statement: All the authors report having no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zheng Li, PhD, Pharmacist, Jiangsu Engineering Research Center of Cardiovascular Drugs Targeting Endothelial Cells, College of Health Sciences, School of Life Sciences, Jiangsu Normal University, No. 101 Shanghai Road, Xuzhou 221000, Jiangsu Province, China. lizhengcpu@163.com
Received: December 26, 2023
Peer-review started: December 26, 2023
First decision: January 4, 2024
Revised: January 8, 2024
Accepted: January 23, 2024
Article in press: January 23, 2024
Published online: February 28, 2024
Core Tip

Core Tip: There are several reviews contributing to the role of gut microbiome in the pathophysiology, therapeutic potential and clinical trials for non-alcoholic fatty liver disease (NAFLD). However, no consensus is available in the literature about the clinical efficacy of fecal microbiota transplantation (FMT) on NAFLD. This is the first review to summarize recent randomized controlled trials for evaluating the effects of FMT on blood lipid profile, liver function, histological changes and other parameters in patients with NAFLD. We also discuss its therapeutic mechanism and propose the obstacles and prospect of FMT in future trials.